The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJohnson Matthey Share News (JMAT)

Share Price Information for Johnson Matthey (JMAT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,742.00
Bid: 1,739.00
Ask: 1,742.00
Change: -24.00 (-1.36%)
Spread: 3.00 (0.173%)
Open: 1,771.00
High: 1,771.00
Low: 1,729.00
Prev. Close: 1,766.00
JMAT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Broker tips: Johnson Matthey, Reckitt Benckiser, Euromoney

Wed, 21st Jul 2010 12:39

Charles Stanley remains equivocal about the investment appeal of the shares of Johnson Matthey, despite a generally robust trading performance in the first quarter of the platinum refiner's financial year.The broker believes that Johnson Matthey's prospects are far from certain. "We note that US sales continue to perform positively, but that economic conditions are likely to deteriorate. We note, too, that Brazil sales have started to slip, for the first time in over a year while the European passenger car market remains extremely tough and that Asia remains highly competitive. More positively, truck production has held up well.," said Jeremy Batstone-Carr, director of private client research at Charles Stanley.The outlook statement from the company indicates that despite easy fiscal second quarter comparative figures, prospects for the second half of the fiscal year remain hard to predict with any accuracy, in Batstone-Carr's view.The broker is sticking with its earnings estimates for the current year and maintaining its "hold" recommendation."We recognise the potential benefits associated with future emissions legislation in heavy duty diesel but suspect that this is already well known by the market," the broker said.Commerzbank has reiterated its neutral stance on household goods maker Reckitt Benckiser after the company announced the earnings boosting acquisition of foot care and prophylactics maker SSL."Combining SSL's strong brands (Durex and Scholl) and Reckitt's distribution power should allow paying £2.5bn, i.e. an EV/EBITDA [enterprise value/earnings before interest, tax, depreciation and amortisation] 2011E [2011 estimate] of 15x," Commerzbank suggests. "The deal should increase EPS [earnings per share] by 3% this year due to low funding costs. However, given the current tough consumer environment in Europe which should be reflected in the Q2 [second quarter] results we maintain our Hold rating," Commerzbank Andreas Riemann said.According to Reckitt, synergies should amount to £100m by the end of 2012. "In light of £126m operating profit this seems an ambitious target in our view but could add another 5% to EPS," Riemann adds.The third quarter update from Euromoney will probably lead to consensus pre-tax profit forecasts edging up to £80m, predicts Singer Capital Markets, despite the business publisher and events organiser sounding a note of caution on the prospects for the fourth quarter."The company has flagged up caution on Q4 [fourth quarter] as it will be driven to a large degree by advertising in September, which faces a tough comp [comparative figure]. The recent weaker profitability of large banks is also a reason for caution and we maintain our view that investors should focus on the September update," suggests Singer analyst Johnathan Barrett.Despite the cautious management comments Barrett thinks the broad picture is encouraging and the return to growth in subscriptions will bolster confidence for the next fiscal year and underpin faith in the business.Singer has a "buy" recommendation on the shares with a 12-month target price of 708p.KBC Peel Hunt is also a buyer, and expects earnings forecasts for the current year will edge up as a result of the trading statement."If we pencil in 8% growth in Q4 (down from our original 11%, and half the rate of Q3 [third quarter]), in line with company comments, this suggests a revenue upgrade of £5m, and (with 40% drop-through) a PBT [profit before tax] increase of £2m. This would give PBT of £80m and EPS [earnings per share] of 50p," KBC analyst Malcolm Morgan said."We do not anticipate changing our FY2011 numbers, given the economic uncertainty," Morgan added.
More News
19 Apr 2024 09:26

LONDON BROKER RATINGS: Peel Hunt starts NatWest and Barclays at 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:

Read more
10 Apr 2024 08:41

Johnson Matthey and BP win deal for US sustainable aviation fuel plant

(Alliance News) - Johnson Matthey PLC and BP PLC on Wednesday said their technology offering has been selected for use in a sustainable aviation fuel plant being built in the US state of Louisiana.

Read more
10 Apr 2024 07:47

LONDON BRIEFING: Stocks called up ahead of US inflation data

(Alliance News) - Stocks in London are called to open higher, as investors shake off nerves ahead of a key US inflation reading.

Read more
9 Apr 2024 09:51

Berenberg hikes target price on Johnson Matthey

(Sharecast News) - Analysts at Berenberg raised their target price on diversified chemicals business Johnson Matthey from 1,650.0p to 1,800.0p on Tuesday but said the performance of its shares will likely depend on three factors.

Read more
9 Apr 2024 08:54

LONDON BROKER RATINGS: Barclays raises Halma to 'overweight'

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
9 Apr 2024 07:39

LONDON BRIEFING: HSBC sells Argentinian arm for USD550 million

(Alliance News) - Stocks in London are called to open lower on Tuesday, as investors nervously look ahead to US inflation data and the European Central Bank's latest interest rate decision.

Read more
25 Mar 2024 10:19

LONDON BROKER RATINGS: SocGen raises Sage; Numis cuts Virgin Money

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
20 Mar 2024 16:54

LONDON MARKET CLOSE: FTSE 100 treads water while Kering weighs on CAC

(Alliance News) - London's FTSE 100 finished the day largely as it started it, enduring an uninspiring session on Wednesday, with the latest Federal Reserve decision about an hour away.

Read more
20 Mar 2024 16:53

London close: Stocks mixed ahead of Fed, BoE decisions

(Sharecast News) - London markets closed with a mixed but little-changed performance on Wednesday, as investors digested a larger-than-expected slowdown in UK inflation.

Read more
20 Mar 2024 11:49

LONDON MARKET MIDDAY: Pre-Fed rate nerves push FTSE 100 in red

(Alliance News) - The FTSE 100 was in the red on Wednesday at midday, as relief from cooling UK inflation was not enough to shake off nerves ahead of the latest US Federal Reserve interest rate decision.

Read more
20 Mar 2024 08:45

LONDON MARKET OPEN: UK inflation cooler than expected ahead of BoE

(Alliance News) - The FTSE 100 in London opened lower on Wednesday morning, with cooler-than-expected inflation doing little to shake off pre-US Federal rate nerves.

Read more
20 Mar 2024 08:32

Johnson Matthey sells medical device components arm for USD700 million

(Alliance News) - Johnson Matthey PLC on Wednesday said it has agreed to sell its Medical Device Components business to Montagu Private Equity LLP, with the proceeds to fund a share buyback.

Read more
20 Mar 2024 07:40

LONDON BRIEFING: UK inflation cools to 3.4% in February; Eyes on Fed

(Alliance News) - Stocks in London are expected to open slightly lower on Wednesday, as investors digest some cooler-than-expected inflation in the UK and look ahead to the latest US interest rate decision.

Read more
20 Mar 2024 07:08

Johnson Matthey sells medical parts unit for $700m

(Sharecast News) - Johnson Matthey is selling its medical device components business to Montagu Private Equity for $700m (£550m), the company said on Wednesday.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.